Gender differences in thyroid cancer: a critical review

References

• Canadian Cancer Society and the National Cancer Institute of Canada. Canadian Cancer Statistics 2008. Toronto, ON, Canada, 1–14 (2008).
   Google Scholar
• Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5., version 2.0, IARC Press, Lyon, France (2004).
   Google Scholar
• Curado MP, Edwards B, Shin HR et al. (Eds). Cancer Incidence in Five Continents, Vol. IX. IARC Scientific Publications No. 160. IARC Press, Lyon, France (2007).
   Google Scholar
• Grubbs EG, Rich TA, Li G et al. Recent advances in thyroid cancer. Curr. Probl. Surg.45(3), 156–250 (2008).
   PubMed Web of Science ®Google Scholar
• Iribarren C, Haselkorn T, Tekawa IS, Friedman GD. Cohort study of thyroid cancer in a San Francisco Bay area population. Int. J. Cancer93, 745–750 (2001).
   PubMed Web of Science ®Google Scholar
• Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery104(6), 947–953 (1988).
   PubMed Web of Science ®Google Scholar
• Brierly JD, Panzarella T, Tsang RW, Gospodarowicz MK, O’Sullivan B. A comparison of different staging systems predictability of patient outcome. Cancer79(12), 2414–2423 (1997).
   Google Scholar
• Farahati J, Bucsky P, Parlowsky T, Mader U, Reiners C. Characteristics of differentiated thyroid carcinoma in children and adolescents with respect to age, gender, and histology. Cancer80(11), 2156–2162 (1997).
   PubMedGoogle Scholar
• dos Santos Silva I, Swerdlow AJ. Sex differences in the risks of hormone-dependent cancers. Am. J. Epidemiol.138(1), 10–28 (1993).
   PubMedGoogle Scholar
• Henderson BE, Ross RK, Pike MC, Casagrande JT. Endogenous hormones as a major factor in human cancer. Cancer Res.42, 3232–3239 (1982).
   PubMed Web of Science ®Google Scholar
• Morganti S, Ceda GP, Saccani M et al. Thyroid disease in the elderly: sex-related differences in clinical expression. J. Endocrinol. Invest.28(11 Suppl. Proceedings), 101–104 (2005).
   PubMedGoogle Scholar
• Libutti SK. Understanding the role of gender in the incidence of thyroid cancer. Cancer J.11(2), 104–105 (2005).
   PubMed Web of Science ®Google Scholar
• Zheng T, Holford TR, Chen Y et al. Time trend and age-period-cohort effect on incidence of thyroid cancer in Connecticut, 1935–1992. Int. J. Cancer67(4), 504–509 (1996).
   Google Scholar
• Liu S, Semeciw R, Ugnat A-M, Mao Y. Increasing thyroid cancer incidence in Canada, 1970–1996: time trends and age-period-cohort effects. Br. J. Cancer86(9), 1335–1339 (2001).
   Google Scholar
• Wang C, Crapo LM. The epidemiology of thyroid disease and the implications for screening. Endocrinol. Metab. Clin. North Am.26(1), 189–218 (1997).
   PubMed Web of Science ®Google Scholar
• [No authors listed]. Clinical guideline, part 1. Screening for thyroid disease. American College of Physicians. Ann. Intern. Med.129(2), 141–143 (1998).
   PubMedGoogle Scholar
• Helfand M, Redfern CC. Clinical guideline, part 2. Screening for thyroid disease: an update. American College of Physicians. Ann. Intern. Med.129(2), 144–158 (1998).
   PubMed Web of Science ®Google Scholar
• Bertakis KD, Azari R, Helms J, Callahan EJ, Robbins JA. Gender differences in the utilization of health care services. J. Fam. Pract.49(2), 147–152 (2000).
   PubMed Web of Science ®Google Scholar
• Verbrugge LM. Sex differences in health. Public Health Rep.97(5), 417–437 (1982).
   PubMed Web of Science ®Google Scholar
• Bertakis KD. The influence of gender on the doctor–patient interaction. Patient Educ. Couns.76(3), 356–360 (2009).
   PubMed Web of Science ®Google Scholar
• Kaplan SH, Gandek B, Greenfield S, Rogers W, Ware JE. Patient and visit characteristics related to physicians’ participatory decision-making style. Med. Care33(12), 1176–1187 (1995).
   PubMed Web of Science ®Google Scholar
• Rasmussen NG, Hornnes PJ, Hegedus L, Feldt-Rasmussen U. Serum thyroglobulin during the menstrual cycle, during pregnancy, and post-partum. Acta Endocrinol. (Copenh).121(2), 168–173 (1989).
   PubMedGoogle Scholar
• Pacchiarotti A, Martino E, Bartalena L et al. Serum thyrotropin by ultrasensitive immunoradiometric assay and serum free thyroid hormones in pregnancy. J. Endocrinol. Invest.9(2), 185–189 (1986).
   PubMed Web of Science ®Google Scholar
• Knudsen N, Bulow I, Laurberg P, Perrild H, Ovesen L, Jorgensen T. Low goiter prevalence among users of oral contraceptives in a population sample of 3712 women. Clin. Endocrinol. (Oxf).57, 71–76 (2002).
   Google Scholar
• Banu SK, Govindarajulu P, Aruldhas MM. Testosterone and estradiol differentially regulate TSH-induced thyrocyte proliferation in immature and adult rats. Steroids67, 573–579 (2002).
   PubMed Web of Science ®Google Scholar
• Frazell EL, Schottenfeld D, Hutter RVP. The prognosis and insurability of thyroid cancer patients. CA Cancer J. Clin.20, 270–275 (1970).
   Google Scholar
• Mitchell I, Livingston EH, Chang AY et al. Trends in thyroid cancer demographics and surgical therapy in the United States. Surgery142(6), 823–828 (2007).
   Google Scholar
• Machens A, Hauptmann S, Dralle H. Disparities between male and female patients with thyroid cancers: sex difference or gender divide? Clin. Endocrinol. (Oxf).65, 500–505 (2006).
   PubMed Web of Science ®Google Scholar
• Loh KC, Greenspan FS, Gee L, Miller TR, Yeo PRB. Pathological tumor–node–metastasis staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J. Clin. Endocrinol. Metab.82(11), 3553–3562 (1997).
   PubMed Web of Science ®Google Scholar
• Ron E, Curtis R, Hoffman DA, Flannery JT. Multiple primary breast and thyroid cancer. Br. J. Cancer49(1), 87–92 (1984).
   PubMed Web of Science ®Google Scholar
• McTiernan A, Weiss NS, Daling JR. Incidence of thyroid cancer in women in relation to known or suspected risk factors for breast cancer. Cancer Res.47, 292–295 (1987).
   PubMed Web of Science ®Google Scholar
• Teppo L, Pukkala E, Saxen E. Multiple cancer – an epidemiologic exercise in Finland. J. Natl Cancer Inst.75, 207–217 (1985).
   PubMed Web of Science ®Google Scholar
• Schottenfeld D, Berg J. Incidence of multiple primary cancers: IV. Cancers of the female breast and genital organs. J. Natl Cancer Inst.46, 161–170 (1971).
   PubMed Web of Science ®Google Scholar
• Chen AY, Levy L, Goepfert H, Brown BW, Spitz MR, Vassilopoulou-Sellin R. The development of breast carcinoma in women with thyroid carcinoma. Cancer92(2), 225–231 (2001).
   Google Scholar
• Navarro Silvera SA, Miller AB, Rohan TE. Risk factors for thyroid cancer: a prospective cohort study. Int. J. Cancer116, 433–438 (2005).
   Google Scholar
• Negri E, Dal Maso L, Ron E et al. A pooled analysis of case-control studies of thyroid cancer: II. Menstrual and reproductive factors. Cancer Causes Control10, 143–155 (1999).
   PubMed Web of Science ®Google Scholar
• Levi F, Franceschi S, Gulie C, Negri E, La Vecchia C. Female thyroid cancer: the role of reproductive and hormonal factors in Switzerland. Oncology50(4), 309–315 (1993).
   PubMed Web of Science ®Google Scholar
• Brindel P, Doyon F, Rachedi F et al. Menstrual and reproductive factors in the risk of differentiated thyroid carcinoma in native women in French Polynesia: a population-based case-control study. Am. J. Epidemiol.167(2), 219–229 (2008).
   PubMed Web of Science ®Google Scholar
• Galanti MR, Hansson L, Lund E et al. Reproductive history and cigarette smoking as risk factors for thyroid cancer in women: a population-based case-control study. Cancer Epidemiol. Biomarkers Prev.5, 425–431 (1996).
   PubMed Web of Science ®Google Scholar
• Memon A, Darif M, Al-Saleh K, Suresh A. Epidemiology of reproductive and hormonal factors in thyroid cancer: evidence from a case-control study in the Middle East. Int. J. Cancer97(1), 82–89 (2002).
   PubMed Web of Science ®Google Scholar
• Sakoda LC, Horn-Ross PL. Reproductive and menstrual history and PTC risk: the San Francisco Bay area thyroid cancer study. Cancer Epidemiol. Biomarkers Prev.11, 51–57 (2002).
   PubMed Web of Science ®Google Scholar
• Mack WJ, Preston-Martin S, Bernstein L, Qian D, Xiang M. Reproductive and hormonal risk factors for thyroid cancer in Los Angeles County females. Cancer Epidemiol. Biomarkers Prev.8(11), 991–997 (1999).
   PubMedGoogle Scholar
• Cady B, Sedgwick CE, Meissner WA, Wool MS, Salzman FA, Werber J. Risk factor analysis in differentiated thyroid cancer. Cancer43(3), 810–820 (1979).
   PubMedGoogle Scholar
• La Vecchia C, Ron E, Franceschi S et al. A pooled analysis of case-control studies of thyroid cancer: III. Oral contraceptives, menopausal replacement therapy and other female hormones. Cancer Causes Control10, 157–166 (1999).
   PubMedGoogle Scholar
• Zivaljevic V, Vlajinac H, Jankovic R et al. Case–control study of female thyroid cancer – menstrual, reproductive and hormonal factors. Eur. J. Cancer Prev.12, 63–66 (2003).
   PubMed Web of Science ®Google Scholar
• Rossing MA, Voigt LF, Wicklund KG, Williams M, Daling JR. Use of exogenous hormones and risk of papillary thyroid cancer (Washington, United States). Cancer Causes Control9, 341–349 (1998).
   PubMedGoogle Scholar
• Ceresini G, Milli B, Morganti S et al. Effect of estrogen therapy for 1 year on thyroid volume and thyroid nodules in postmenopausal women. Menopause15(2), 326–331 (2008).
   Google Scholar
• Akslen LA, Nilssen S, Kvale G. Reproductive factors and risk of thyroid cancer. A prospective study of 63,090 women from Norway. Br. J. Cancer65, 772–774 (1992).
   Web of Science ®Google Scholar
• Pham TM, Fujino Y, Mikami H et al. Reproductive and menstrual factors and thyroid cancer among Japanese women: the Japan Collaborative Cohort Study. J. Womens Health18(3), 331–335 (2009).
   Google Scholar
• Hallquist A, Hardell L, Degerman A, Boquist L. Thyroid cancer: reproductive factors, previous diseases, drug intake, family history and diet. A case–control study. Eur. J. Cancer Prev.3, 481–488 (1994).
   PubMedGoogle Scholar
• Dal Maso L, La Vecchia C, Franceschi S et al. A pooled analysis of thyroid cancer studies: V. Anthropometric factors. Cancer Causes Control11, 137–144 (2000).
   PubMed Web of Science ®Google Scholar
• Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet371, 569–578 (2008).
   PubMed Web of Science ®Google Scholar
• Guignard R, Truong T, Rougier Y, Baron-Dubourdieu D, Guenel P. Alcohol drinking, tobacco smoking, and anthropometric characteristics as risk factors for thyroid cancer: a countrywide case–control study in New Caledonia. Am. J. Epidemiol.166(10), 1140–1149 (2007).
   PubMed Web of Science ®Google Scholar
• Engeland A, Tretli S, Akslen LA, Bjorge T. Body size and thyroid cancer in two million Norwegian men and women. Br. J. Cancer95, 366–370 (2006).
   PubMed Web of Science ®Google Scholar
• Goodman MT, Kolonel LN, Wilkens LR. The association of body size, reproductive factors and thyroid cancer. Br. J. Cancer66(6), 1180–1184 (1992).
   Google Scholar
• Endogenous Hormones Breast Cancer Collaborative Group. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J. Natl Cancer Inst.95(16), 1218–1226 (2003).
   PubMed Web of Science ®Google Scholar
• Manole D, Schildknecht B, Gosnell B, Adams E, Derwahl M. Estrogen promotes growth of human thyroid tumor cells by different molecular mechanisms. J. Clin. Endocrinol. Metab.86(3), 1072–1077 (2001).
   PubMed Web of Science ®Google Scholar
• Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am. J. Med.97, 418–428 (1994).
   PubMed Web of Science ®Google Scholar
• Salvesan H, Njolstad PR, Akslen LA, Albrektsen G, Soreide O, Varhaug JE. Papillary thyroid carcinoma: a multivariate analysis of prognostic factors including an evaluation of the p-TNM staging system. Eur. J. Surg.158(11–12), 583–589 (1992).
   Google Scholar
• Byar DP, Green SB, Dor P et al. A prognostic index for thyroid carcinoma: a study of the E.O.R.T.C. thyroid cancer cooperative group. Eur. J. Cancer15, 1033–1041 (1979).
   PubMed Web of Science ®Google Scholar
• Cunningham MP, Duda RP, Recant W, Chmiel JS, Sylvester J, Fremgen A. Survival discriminants for differentiated thyroid cancer. Am. J. Surg.160(4), 344–347 (1990).
   PubMedGoogle Scholar
• Lundgren CI, Hall P, Ekbom A, Frisell J, Zedenius J, Dickman PW. Incidence and survival of Swedish patients with differentiated thyroid cancer. Int. J. Cancer.106, 569–573 (2003).
   PubMed Web of Science ®Google Scholar
• Levi F, Randimbison L, Te VC, La Vecchia C. Thyroid cancer in Vaud, Switzerland: an update. Thyroid12(2), 163–168 (2002).
   Google Scholar
• Shaha AR, Shah JP, Loree TR. Risk group stratification and prognostic factors in papillary carcinoma of thyroid. Ann. Surg. Oncol.3(6), 534–538 (1996).
   PubMedGoogle Scholar
• Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid cancer: a population-based study of 15,698 cases from the Surveillance, Epidemiology, and End Results (SEER) program 1973–1991. Cancer79(3), 564–573 (1997).
   PubMed Web of Science ®Google Scholar
• Levi F, Franceschi S, Te VC, Negri E, La Vecchia C. Descriptive epidemiology of thyroid cancer in the Swiss Canton of Vaud. J. Cancer Res. Clin. Oncol.116(6), 639–647 (1990).
   Google Scholar
• Kjellman P, Zedenius J, Lundell G et al. Predictors of outcome in patients with papillary thyroid carcinoma. Eur.J. Surg. Oncol.32(3), 345–352 (2005).
   Google Scholar
• Jukkola A, Bloigu R, Ebeling T, Salmela P, Blanco G. Prognostic factors in differentiated thyroid carcinomas and their implications for current staging classifications. Endocr. Relat. Cancer11(3), 571–579 (2004).
   PubMed Web of Science ®Google Scholar
• Kushchayeva Y, Duh QY, Kebebew E, D’Avanzo A, Clark O. Comparison of clinical characteristics at diagnosis and during follow-up in 118 patients with Hurthle cell or follicular thyroid cancer. Am. J. Surg.195, 457–462 (2007).
   Google Scholar
• Wada N, Hasegawa S, Masudo Y et al. Clinical outcome by AMES risk definition in Japanese differentiated thyroid carcinoma patients. Asian J. Surg.30(2), 102–107 (2007).
   Google Scholar
• Haigh P, Urbach D, Rotstein L. AMES prognostic index and extent of thyroidectomy for well-differentiated thyroid cancer in the United States. Surgery136(3), 609–616 (2004).
   Google Scholar
• Machens A, Holzhausen H, Lautenschlager C, Thanh PN, Dralle H. Enhancement of lymph node metastasis and distant metastasis of thyroid carcinoma: a multivariate analysis of clinical risk factors. Cancer98(4), 712–719 (2003).
   PubMedGoogle Scholar
• Yamamoto Y, Maeda T, Izumi K, Otsuka H. Occult papillary carcinoma of the thyroid: a study of 408 autopsy cases. Cancer65(5), 1173–1179 (1990).
   PubMed Web of Science ®Google Scholar
• Mangelsdorf DJ, Thummel C, Beato M et al. The nuclear receptor superfamily: the second decade. Cell83(6), 835–839 (1995).
   PubMed Web of Science ®Google Scholar
• Simoncini T, Genazzani AR. Non-genomic actions of sex steroid hormones. Eur. J. Endocrinol.148, 281–292 (2003).
   PubMed Web of Science ®Google Scholar
• Levin ER. Rapid signaling by steroid receptors. Am. J. Physiol. Regul. Integr. Comp. Physiol.295, R1425–R1430 (2008).
   Google Scholar
• Pedram A, Razandi M, Sainson RCA, Kim JK, Hughes CC, Levin ER. A conserved mechanism for steroid receptor translocation to the plasma membrane. J. Biol. Chem.282(31), 22278–22288 (2007).
   PubMed Web of Science ®Google Scholar
• Levin ER. Integration of the extranuclear and nuclear actions of estrogen. Mol. Endocrinol.19(8), 1951–1959 (2005).
   PubMed Web of Science ®Google Scholar
• Hiroi H, Inoue S, Watanabe T et al. Differential immunolocalization of estrogen receptor α and β in rat ovary and uterus. J. Mol. Endocrinol.22(1), 37–44 (1999).
   PubMed Web of Science ®Google Scholar
• Nilsson S, Makela S, Treuter E et al. Mechanisms of estrogen action. Physiol. Rev.81, 1535–1565 (2001).
   PubMed Web of Science ®Google Scholar
• McDonnell DP, Norris JD. Connections and regulation of the human estrogen receptor. Science296, 1642–1644 (2002).
   PubMed Web of Science ®Google Scholar
• Wierman ME. Sex steroid effects at target tissues – mechanism of action. Adev. Physiol. Educ.31, 26–33 (2007).
   PubMed Web of Science ®Google Scholar
• Giangrande PH, McDonnell DP. The A and B isoforms of the human progesterone receptor: two functionally different transcriptional factors encoded by single gene. Recent Prog. Horm. Res.54, 291–313 (1999).
   PubMedGoogle Scholar
• Vegeto E, Shahbaz MM, Wen DX, Goldman ME, O’Malley BW, McDonnell DP. Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. Mol. Endocrinol.7(10), 1244–1255 (1993).
   PubMed Web of Science ®Google Scholar
• Kastner P, Krust A, Turcotte B et al. distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone forms A and B. EMBO J.9(5), 1603–1614 (1990).
   PubMed Web of Science ®Google Scholar
• Graham JD, Clarke CL. Physiological action of progesterone in target tissues. Endocr. Rev.18(4), 502–519 (1997).
   PubMed Web of Science ®Google Scholar
• Tenbaum S, Baniahmad A. Nuclear receptors: structure, function and involvement in disease. Int. J. Biochem. Cell Biol.29(12), 1325–1341 (1997).
   PubMedGoogle Scholar
• Keller ET, Ershler WB, Chang C. The androgen receptor: a mediator of diverse responses. Front. Biosci.1, D59–D71 (1996).
   PubMedGoogle Scholar
• Platet N, Cathiard AM, Gleizes M, Garcia M. Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion. Crit. Rev. Oncol. Hematol.51(1), 55–67 (2004).
   PubMed Web of Science ®Google Scholar
• Chambers JT. Sex steroids in endometrial cancer. Yale J. Biol. Med.61(4), 339–350 (1988).
   Google Scholar
• Stabile LP, Siegfried JM. Estrogen receptor pathways in lung cancer. Curr. Oncol. Rep.6(4), 259–267 (2004).
   Google Scholar
• Pignata S, Daniele B, Gallo C, De Vivo R, Monfardini S, Perrone F. Endocrine treatment of hepatocellular carcinoma: any evidence of benefit? Eur. J. Cancer34(1), 25–32 (1998).
   PubMed Web of Science ®Google Scholar
• Di Maio M, Daniele B, Pignata S et al. Is human hepatocellular carcinoma a hormone-responsive tumor? World J. Gastroenterol.14(11), 1682–1689 (2008).
   Google Scholar
• Nagasue N, Kohno H. Hepatocellular carcinoma and sex hormones. HPB Surgery6(1), 1–6 (1992).
   Google Scholar
• Wong NA, Malcomson RD, Jodrell DI, Groome NP, Harrison DJ, Saunders PT. ERβ isoform expression in colorectal carcinoma: an in vivo and in vitro study of clinicopathological and molecular correlates. J. Pathol.207(1), 53–60 (2005).
   PubMedGoogle Scholar
• Pravdenkova S, Al-Mefty O, Sawyer J, Husain M. Progesterone and estrogen receptors: opposing prognostic indicators in meningiomas. J. Neurosurg.105(2), 163–173 (2006).
   PubMed Web of Science ®Google Scholar
• Roser F, Nakamura M, Bellinzona M, Rosahl SK, Ostertag H, Samii M. The prognostic value of progesterone receptor status in meningiomas. J. Clin. Pathol.57(10), 1033–1037 (2004).
   PubMed Web of Science ®Google Scholar
• Avila DM, Zoppi S, McPhaul MJ. The androgen receptor (AR) in syndromes of androgen insensitivity and in prostate cancer. J. Steroid Biochem. Mol. Biol.76(1–5), 135–142 (2001).
   Google Scholar
• Pijnenborg JMA, Romano A, Dam-de Veen GC et al. Aberrations in the progesterone receptor gene and the risk of recurrent endometrial carcinoma. J. Pathol.205(5), 597–605 (2005).
   Google Scholar
• Simpson E, Rubin G, Clyne C et al. Local estrogen biosynthesis in males and females. Endocr. Relat. Cancer6(2), 131–137 (1999).
   PubMed Web of Science ®Google Scholar
• Longcope C. Adrenal and gonadal secretion in normal females. Clin. Endocrinol. Metab.15(2), 213–228 (1986).
   PubMedGoogle Scholar
• Utian WH. Menopause-related definitions. Int. Congr. Series1266, 133–138 (2004).
   Google Scholar
• Chahal HS, Drake WM. The endocrine system and ageing. J. Pathol.211, 173–180 (2007).
   PubMed Web of Science ®Google Scholar
• Santoro N, Adel T, Skurnick JH. Decreased inhibin tone and increased activin A secretion characterize reproductive aging in women. Fertil. Steril.71(4), 658–662 (1999).
   Google Scholar
• Welt CK, McNicholl DJ, Taylor AE, Hall JE. Female reproductive aging in marked by decreased secretion of dimeric inhibin. J. Clin. Endocrinol. Metab.84, 105–111 (1999).
   PubMed Web of Science ®Google Scholar
• Santoro N, Brown JR, Adel T, Skurnick JH. Characterization of reproductive hormonal dynamics in the perimenopause. J. Clin. Endocrinol. Metab.81, 1495–1501 (1996).
   PubMed Web of Science ®Google Scholar
• Burger HG, Hale GE, Robertson DM, Dennerstein L. A review of hormonal changes during the menopausal transition: focus on findings from the Melbourne Women’s Midlife Health Project. Hum. Reprod. Update13(6), 559–565 (2007).
   PubMed Web of Science ®Google Scholar
• Sherman BM, West JH, Korenman SG. The menopausal transition: analysis of LH, FSH, estradiol, and progesterone concentrations during menstrual cycles of older women. J. Clin. Endocrinol. Metab.42(4), 629–636 (1976).
   PubMed Web of Science ®Google Scholar
• Burger H. The menopausal transition – endocrinology. J. Sex. Med.5(10), 2266–2273 (2008).
   PubMed Web of Science ®Google Scholar
• Simon JA. Estrogen replacement therapy: effects on the endogenous androgen milieu. Fertil. Steril.77(S4), 77–82 (2002).
   PubMed Web of Science ®Google Scholar
• Burger HG. Androgen production in women. Fertil. Steril.77(Suppl. 4), 3–5 (2002).
   PubMed Web of Science ®Google Scholar
• Tahboub R, Arafah BM. Sex steroids and the thyroid. Best Pract. Res. Clin. Endocrinol. Metab.23, 769–780 (2009).
   Web of Science ®Google Scholar
• del Senno L, degli Uberti E, Hanau S, Piva R, Rossi R, Trasforini G. In vitro effects of estrogen on tgb and c-myc gene expression in normal and neoplastic human thyroids. Mol. Cell Endocrinol.63(1–2), 67–74 (1989).
   PubMed Web of Science ®Google Scholar
• Furlanetto TW, Nguyen LQ, Jameson JL. Estradiol increases proliferation and down-regulates the sodium/iodide symporter gene in FRTL-5 cells. Endocrinology140(12), 5705–5711 (1999).
   Google Scholar
• Christianson D, Roti E, Vagenakis AG, Braverman LE. The sex-related difference in serum thyrotropin concentration is androgen mediated. Endocrinology108(2), 529–535 (1981).
   PubMed Web of Science ®Google Scholar
• Rajoria S, Suriano R, Shanmugam A et al. Metastatic phenotype is regulated by estrogen in thyroid cells. Thyroid20(1), 33–41 (2010).
   PubMed Web of Science ®Google Scholar
• Dalla Valle LD, Ramina A, Vianello S, Fassina A, Belvedere P, Colombo L. Potential for estrogen synthesis and action in human normal and neoplastic thyroid tissues. J. Clin. Endocrinol. Metab.83(10), 3702–3709 (1998).
   Google Scholar
• Kawabata W, Suzuki T, Moriya T et al. Estrogen receptors (α and β) and 17 β-hydroxysteroid dehydrogenase type 1 and 2 in thyroid disorders: possible in situ estrogen synthesis and actions. Mod. Pathol.16(5), 437–444 (2003).
   PubMedGoogle Scholar
• Mori M, Naito M, Watanabe H, Takeichi N, Dohi K, Ito A. Effects of sex difference, gonadectomy, and estrogen on N-methyl-N-nitrosourea induced rat thyroid tumors. Cancer Res.50, 7662–7667 (1990).
   Google Scholar
• Thiruvengadam A, Govindarajulu P, Aruldhas MM. Modulatory effect of estradiol and testosterone on the development of N-nitrosodiisopropranolamine induced thyroid tumors in female rats. Endocr. Res.29(1), 43–51 (2003).
   PubMed Web of Science ®Google Scholar
• Bosland MC, Prinsen MK, Rivenson A, Weisburger JH. Induction of skin and thyroid tumors in male rats by N-methyl-N-nitrosourea after sequential treatment with cyproterone acetate and testosterone proprionate: effects of castration, rat strain and time of carcinogen injection. Carcinogenesis13(4), 669–674 (1992).
   Google Scholar
• Hofmann C, Oslapas R, Nayyar R, Paloyan E. Androgen-mediated development of irradiation-induced thyroid tumors in rats: dependence on animal age during interval of androgen replacement in castrated males. J. Natl Cancer Inst.77(1), 253–260 (1986).
   Google Scholar
• Hofmann C, Oslapas R, Nayyar R, McCall A, Paloyan E. Testosterone enhancement of thyroid carcinoma in rats: the role of TSH. Surgery100(6), 1078–1087 (1986).
   Google Scholar
• Banu SK, Govindarajulu P, Aruldhas MM. Testosterone and estradiol have specific differential modulatory effect on the proliferation of human thyroid papillary and follicular carcinoma cell lines independent of TSH action. Endocr. Pathol.12(3), 315–327 (2001).
   Google Scholar
• Lee ML, Chen GG, Vlantis AC, Tse GM, Leung BC, van Hasselt CA. Induction of thyroid papillary carcinoma cell proliferation by estrogen is associated with an altered expression of Bcl-xL. Cancer J.11(2), 113–121 (2005).
   PubMedGoogle Scholar
• Zeng Q, Chen GG, Vlantis AC, van Hasselt CA. Oestrogen mediates the growth of human thyroid carcinoma via an oestrogen receptor–ERK pathway. Cell Prolif.40, 921–935 (2007).
   PubMed Web of Science ®Google Scholar
• Inoue H, Oshimo K, Miki H, Kawano M, Monden Y. Immunohistochemical study of estrogen receptors and the responsiveness to estrogen in papillary thyroid carcinoma. Cancer72(4), 1364–1368 (1993).
   Google Scholar
• Kavanagh DO, McIlroy M, Myers E et al. The role of oestrogen receptor α in human thyroid cancer: contributions from coregulatory proteins and the tyrosine kinase receptor HER2. Endocr. Relat. Cancer17(1), 255–264 (2010).
   Google Scholar
• Farid NR, Shi Y, Zou M. Molecular basis of thyroid cancer. Endocr. Rev.15(2), 202–232 (1994).
   PubMedGoogle Scholar
• Vivacqua A, Bonofiglio D, Albanito L et al. 17-estradiol, genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the G protein-coupled receptor GPR30. Mol. Pharmacol.70, 1414–1423 (2006).
   PubMed Web of Science ®Google Scholar
• Zeng Q, Chen GG, Vlantis AC, Tse GM, van Hasselt CA. The contributions of oestrogen receptor isoforms to the development of papillary and anaplastic thyroid carcinomas. J. Pathol.214, 425–433 (2008).
   Google Scholar
• Schweppe RE, Klopper JP, Korch C et al. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J. Clin. Endocrinol. Metab.93(11), 4331–4341 (2008).
   PubMed Web of Science ®Google Scholar
• Chen GG, Vlantis AC, Zeng Q, van Hasselt CA. Regulation of cell growth by estrogen signaliing and potential targets in thyroid cancer. Curr. Cancer Drug Targets8, 367–377 (2008).
   PubMedGoogle Scholar
• Kossmehl P, Shakibaei M, Cogoli A et al. Weightlessness induced apoptosis in normal thyroid cells and papillary thyroid carcinoma cells via extrinsic and intrinsic pathways. Endocrinology144(9), 172–179 (2003).
   Google Scholar
• Memon GR, Arain SA, Jamal Q, Ansari T. Immunohistochemical study of progesterone receptors in thyroid gland. J. Pak. Med. Assoc.55, 321–324 (2005).
   Google Scholar
• Roswell P, Bu S, Rubin K, Landstrom M, Heldin NE. 2-methoxyestradiol induces apoptosis in cultured human anaplastic thyroid carcinoma cells. Thyroid12(2), 143–150 (2006).
   Google Scholar
• Mueck AO, Seeger H. 2-methoxyestradiol – biology and mechanism of action. Steroids75(10), 625–631 (2010).
   PubMed Web of Science ®Google Scholar
• Fujimoto N, Sakai Y, Ito A. Increase in estrogen receptor levels in MNU-induced thyroid tumors in LE rats. Carcinogenesis13(8), 1315–1318 (1992).
   Google Scholar
• Molteni A, Bahu RM, Battifora HA et al. Estradiol receptor assays in normal and neoplastic tissues. A possible diagnostic acid for tumor differentiation. Ann. Clin. Lab. Sci.9(2), 103–108 (1979).
   PubMedGoogle Scholar
• Molteni A, Warpeha RL, Brizio-Molteni L, Fors EM. Estradiol receptor-binding protein in head and neck neoplastic and normal tissue. Arch. Surg.116, 207–210 (1981).
   PubMedGoogle Scholar
• Clark OH, Gerend PL, Davis M, Goretzki PE, Hoffman PG. Estrogen and thyroid-stimulating hormone receptors in neoplastic and non-neoplastic human thyroid tissue. J. Surg. Res.38, 89–96 (1985).
   Google Scholar
• Hampl R, Nemec J, Heresova J, Kimlova I, Starka L. Estrogen receptors in human goitrous and neoplastic thyroid. Endocrinol. Exp.19, 227–230 (1985).
   Google Scholar
• Hong GS, Sng IT, Soo KC. Oestrogen receptors in well-differentiated thyroid cancers. Ann. Acad. Med. Singapore20(6), 767–769 (1991).
   Google Scholar
• Jaklic BR, Rushin J, Ghosh BC. Estrogen and progesterone receptors in thyroid lesions. Ann. Surg. Oncol.2(5), 429–434 (1995).
   Google Scholar
• Karlsson MG, Hardell L, Hallquist A. No association between immunohistochemical expression of p53, c-erbb-2, Ki-67, estrogen and progesterone receptors in female papillary thyroid cancer and ionizing radiation. Cancer Lett.120, 173–177 (1997).
   Google Scholar
• Arain SA, Shah MH, Meo SA, Jamal Q. Estrogen receptors in human thyroid gland. An immunohistochemical study. Saudi Med. J.24(2), 174–178 (2003).
   Google Scholar
• Chauduri PK, Prinz R. Estrogen receptor in normal and neoplastic human thyroid tissue. Am. J. Otolaryngol.10(5), 322–326 (1989).
   Google Scholar
• Lewy-Trenda I. Estrogen and progesterone receptors in neoplastic and non-neoplastic thyroid lesions. Pol. J. Pathol.53(2), 67–72 (2002).
   PubMedGoogle Scholar
• Miki H, Oshimo K, Inoue H, Morimoto T, Monden Y. Sex hormone receptors in human thyroid tissues. Cancer66, 1759–1762 (1990).
   Google Scholar
• van Hoeven KH, Menendez-Botet CJ, Strong EW, Huvos AG. Estrogen and progesterone receptor content in human thyroid disease. Am. J. Clin. Pathol.99, 175–181 (1993).
   Google Scholar
• Bonacci R, Pinchera A, Fierabacci P, Giglotti A, Grasso L, Giani C. Relevance of estrogen and progesterone enzyme immunoassay in malignant, benign and surrounding normal thyroid tissue. J. Endocrinol. Invest.19(3), 159–164 (1996).
   Google Scholar
• Prinz RA, Sandberg L, Chaudhuri PK. Androgen receptors in human thyroid tissue. Surgery96(9), 996–1000 (1984).
   Google Scholar
• Tavangar SM, Monajemzadeh M, Larijani B, Haghpanah V. Immunohistochemical study of oestrogen receptors in 351 human thyroid glands. Singapore Med. J.48(8), 744–747 (2007).
   Google Scholar
• Hiasa Y, Nishioka H, Kitahori Y et al. Immunohistochemical analysis of estrogen receptors in 313 paraffin section cases of human thyroid tissue. Oncology50, 132–136 (1993).
   PubMedGoogle Scholar
• Diaz NM, Mazoujian G, Wick MR. Estrogen-receptor protein in thyroid neoplasms: an immunohistochemical analysis of papillary carcinoma, follicular carcinoma, and follicular adenoma. Arch. Pathol. Lab. Med.115, 1203–1207 (1991).
   PubMed Web of Science ®Google Scholar
• Lee CH, Kao HL, Lin HS, Peng FK, Chi CW. Estrogen receptors and glucocorticoid receptors in human well-differentiated thyroid cancer. Int. J. Mol. Med.2, 229–233 (1998).
   Google Scholar
• Kansakar E, Chang YJ, Mehrabi M, Mittal V. Expression of estrogen receptor, progesterone receptor, and vascular endothelial growth factor-A in thyroid cancer. Am. Surg.75, 785–789 (2009).
   PubMed Web of Science ®Google Scholar
• Egawa C, Miyoshi Y, Iwao K, Shiba E, Noguchi S. Quantitative analysis of estrogen receptor-α and -β messenger RNA expression in normal and malignant thyroid tissues by real-time polymerase chain reaction. Oncology62, 293–298 (2001).
   Google Scholar
• Takeichi N, Ito H, Haruta R, Matsuyama T, Dohi K, Tahara E. Relation between estrogen receptor and malignancy of thyroid cancer. Jpn. J. Cancer Res.82, 19–22 (1991).
   Google Scholar
• Inoue H, Oshimo K, Miki H et al. Immunohistochemical study of estrogen receptor and estradiol on papillary thyroid carcinoma in young patients. J. Surg. Oncol.53, 226–230 (1993).
   Google Scholar
• Wiseman SM, Masoudi H, Niblock P et al. Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. Ann. Surg. Oncol.14(2), 719–729 (2007).
   PubMed Web of Science ®Google Scholar
• Wiseman SM, Griffith OL, Deen S et al. Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma. Arch. Surg.142(8), 717–729 (2007).
   PubMedGoogle Scholar
• Mizukami Y, Michigishi T, Nonomura A, Hashimoto T, Noguchi M, Matsubara F. Estrogen and estrogen receptors in thyroid carcinomas. J. Surg. Oncol.47, 165–169 (1991).
   Google Scholar
• Imai Y, Yamakawa M, Matsuda M, Kasajima T. Endogenous sex hormone and estrogen binding activity in thyroid cancer. Histol. Histopathol.4(1), 39–45 (1989).
   PubMedGoogle Scholar
• Yane K, Kitahori Y, Konishi N et al. Expression of the estrogen receptor in human thyroid neoplasms. Cancer Lett.84(1), 59–66 (1994).
   Google Scholar
• Metaye T, Millet C, Kraimps JL, Aubouin B, Barbier J, Begon F. Estrogen receptors and cathepsin D in human thyroid tissue. Cancer52(6), 1991–1996 (1993).
   Google Scholar
• Poulsen HS, Bukh A, Rytter L et al. Oestrogen receptor assay: false positive analysis? Acta Radiol. Oncol.23(2–3), 109–117 (1984).
   PubMed Web of Science ®Google Scholar
• Anderson KM, Bonomi P, Marogil M, Hendrickson C, Economou S. Comparison of dextran-coated charcoal and sucrose density gradient analyses of estrogen and progesterone receptors in human breast cancer. Cancer Res.40, 4127–4132 (1980).
   PubMedGoogle Scholar
• Pavao M, Traish AM. Estrogen receptor antibodies: specificity and utility in detection, localization and analyses of estrogen receptor α and β. Steroids66(1), 1–16 (2001).
   PubMedGoogle Scholar
• Colomer A, Martinez-Mas JV, Matias-Guiu X et al. Sex-steroid hormone receptora in human medullary thyroid carcinoma. Mod. Pathol.9(1), 68–72 (1996).
   Google Scholar
• Blechet C, Lecomte P, De Calan L et al. Expression of sex steroid hormone receptors in C cell hyperplasia and medullary thyroid carcinoma. Virchows Arch.450(4), 433–439 (2007).
   Google Scholar